India is the 'Pharmacy of the World' yet struggles with API import dependence. Examine.

India is the third-largest drug producer by volume, supplying about 20% of global generics and 60% of the world's vaccines [2]. Yet this formulation strength rests on imported bulk drugs — a paradox of scale without depth in the value chain.

Basis of the 'Pharmacy of the World' claim

• Global supply role: exports to 200+ countries; dominant share of WHO's vaccine demand for DPT, BCG and measles [2].
• Domestic affordability: Jan Aushadhi Kendras grew from 84 (2014) to 19,200+ (2026), saving citizens ₹40,000 crore+ [1]; generics priced 50–90% below branded equivalents [4].
• Manufacturing scale-up: PLI for pharma and medical devices has drawn cumulative investment of ₹42,694 crore, sales of ₹3.43 lakh crore and 1.13 lakh+ jobs [1].

The API dependence problem

• Import reliance: India imports a large share of critical bulk drugs, KSMs and drug intermediates, with sourcing heavily concentrated in China [3].
• Cause — economics, not capability: imports persist "largely for economic considerations" [3] — cost disadvantage in fermentation-based APIs, absence of scale, and high utility and common-infrastructure costs.
• Strategic vulnerability: COVID-19 supply shocks showed how a single-source disruption can halt essential-medicine production.
• Value trap: third by volume but only 14th by value [2] — low-margin generics with limited innovation depth.

Corrective architecture

• PLI for Bulk Drugs (₹6,940 crore, 2020) — actual investment reached ₹4,570 crore by March 2025, exceeding commitments [3].
• Bulk Drug Parks: three sanctioned in Andhra Pradesh, Gujarat and Himachal Pradesh, with grant-in-aid up to ₹1,000 crore each for shared infrastructure [3].
• PRIP (₹5,000 crore) shifts the sector from cost-based to innovation-based growth [2].

India's dependence is a structural cost gap rather than a technological one, and is therefore correctable. Sustaining park utilisation, green-chemistry process innovation and predictable fiscal support beyond scheme timelines can convert volume leadership into value leadership — securing both Atmanirbharta and the affordable-access promise underlying SDG-3.